CD8 T-Cells and Host Defense Against P. Carinii
CD8 T-Cells and Host Defense Against P. Carinii
批准号:
7822469
负责人:
JAY K KOLLS
金额:
$0.77万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2010-08-31
关键词:
Adoptive TransferAntigensBiological AssayBone MarrowCD4 Lymphocyte CountCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCXCR3 geneCellsClinicalComplicationDataDendritic CellsEffector CellFundingGene TransferGenesGrantHIV InfectionsHost DefenseHost Defense MechanismImmunocompromised HostImmunotherapyIn VitroInfectionInterferon Type IIInterferonsInterleukin-15Knockout MiceLeadLiquid substanceLungMaintenanceMediatingMethodsModelingMononuclearMusOpportunistic InfectionsPatientsPhagocytesPhenotypePhysiologic pulsePneumocystis InfectionsPneumocystis cariniiPneumocystis carinii PneumoniaPopulationProductionProteinsPublishingRecruitment ActivityRiskRoleSignal TransductionSmall Inducible Cytokine B9Structure of parenchyma of lungT memory cellT-LymphocyteTestingTimeadenoviral-mediatedbasechemokinechemokine receptorcytokinedesignin vitro activityin vivokillingsmacrophagemouse modelnoveloverexpressionpathogenreceptorreconstitutionresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Despite current strategies to treat HIV infection and its complications, Pneumocystis carinii pneumonia (PCP) remains a common clinical problem. Although there is a well-known relationship between CD4+ lymphocyte count and the risk of PC infection, the role of mononuclear phagocytes, CD8+ cells, gamma/delta T cells, and their secreted cytokines in host defense against this infection are far less clear. During the prior funding period, we have demonstrated that Tcl CD8+ T-cells, as defined by strong endogenous interferon-gamma (IFN) production, are associated with eradication of PC in the absence of CD4+ T-cells. Preliminary studies in our lab using a novel in vitro PC killing assay demonstrate that Tcl CD8+ T-cells have preferential PC killing activity and also augment macrophage-mediated killing. Based on these studies we hypothesize that specific subsets of CD8+ T-cells are effector cells against PC. We will test this hypothesis with the following Specific Aims. Specific Aim 1. Our hypothesis predicts that overexpression of IFN-g, using adenoviral-mediated gene transfer (ADIFN) will enhance recruitment of CXCR3+, CD8 + T-cells with a Tcl phenotype. Specific Aim 2. Our hypothesis predicts that these CXCR3+ cells are required for CD8+ T-cell mediated clearance of PC in the AdlFN model. Specific Aim 3. Our hypothesis predicts that CXCR3+/Tcl+/CD8+ T-cells have preferential killing of PC in vitro and effect clearance of P. carinii in the reconstituted scid mouse model, compared to other CD8+ T-cell populations. These studies will investigate non-CD4 dependent host defenses utilizing a novel form of immunotherapy against an important opportunistic pathogen. The results of these studies will not only aid us in further understanding lung host defenses, but also may lead to novel methods of therapy for opportunistic infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tulane StARR Program
-
批准号:10608042
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2021
-
负责人:JAY K KOLLS
-
依托单位:
Tulane StARR Program
-
批准号:10318191
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2021
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:9981924
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10443796
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10227140
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10671653
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10321572
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10559497
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Training in CD4 T-cell Lung Immunity
-
批准号:9804524
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9250044
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9128312
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10521311
-
项目类别:
-
资助金额:$47.95万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:9210593
-
项目类别:
-
资助金额:$24.87万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10375091
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:8990110
-
项目类别:
-
资助金额:$8.62万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:9193101
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Core C RNA Sequencing and Bioinformatics
-
批准号:8853015
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
-
批准号:8932653
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2014
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8130158
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8255486
-
项目类别:
-
资助金额:$21.74万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: